RLYB - Rallybio Corp

10.705
-0.265   -2.475%

Share volume: 481,314
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$10.97
-0.27
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
43%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
41.98%
1 Month
1,761.09%
3 Months
1,505.91%
6 Months
1,726.79%
1 Year
1,387.63%
2 Year
443.40%
Key data
Stock price
$10.70
P/E Ratio 
0.00
DAY RANGE
$10.30 - $11.49
EPS 
-$0.45
52 WEEK RANGE
$0.22 - $11.49
52 WEEK CHANGE
$1,438.07
MARKET CAP 
20.851 M
YIELD 
N/A
SHARES OUTSTANDING 
42.244 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$676,070
AVERAGE 30 VOLUME 
$287,119
Company detail
CEO: Martin W. MacKay
Region: US
Website: rallybio.com
Employees: 40
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)

Recent news